Baylor College of Medicine Cancer Center

描述：(申请人描述)新成立的贝勒医学院癌症中心(BCMCC)寻求P20规划拨款，目的是提交P30申请NCI癌症中心支持拨款，并在未来24-36个月内被指定为综合癌症中心。我们的总体目标是统一和组织强大的、独立的科学项目，使其成为一个运作良好的癌症中心。BCMCC为贝勒医学院(BCM)和四家大型教学医院(本陶布综合医院、卫理公会医院、德克萨斯儿童医院和休斯顿退伍军人管理医院)服务，2001年这四家医院新增了5000例癌症病例。BCM有5000万美元的癌症研究支持，NCI提供了约3400万美元的支持。基础、转化和临床研究在八个项目中进行：乳腺癌(由C.Kent Osborne医学博士领导)；癌症生物学(由Dennis R.Roop博士领导)；癌症预防和人口科学(由Powel H.Brown医学博士领导)；细胞和基因治疗(由Malcolm K.Brenner医学博士领导)；细胞周期控制、肿瘤抑制因子、病毒和癌基因(由J.Wade Harper博士领导)；核受体生物学(由Orla M.Conneely博士领导)；前列腺癌(由Timothy C.Thompson博士领导)；以及儿科癌症(由David G.Poplack医学博士领导)。14个共享资源/核心支持这一努力。Michael W.Lieberman，医学博士，担任中心主任，直接向BCM总裁报告。副主任包括：伯特·W·奥马利医学博士(基础科学)、奥斯本博士(临床科学)、布朗博士(癌症预防、外联和卫生服务)和芭芭拉·G·科克伦女士(行政管理)。管理掌握在一个执行委员会手中，执行委员会由利伯曼博士担任主席，由四名副主任和其他七名BCMCC成员组成。哈罗德·L·摩西医学博士担任外部咨询委员会主席，苏珊·M·贝吉特博士担任内部咨询委员会主席。为了准备P30申请，我们制定了一份详细的战略计划，并制定了时间表。我们的P20具体目标是：1.加强对BCMCC的行政领导、内部治理和机构支持；2.增加BCMCC成员之间的互动，促进翻译研究；3.发展对共享资源/核心项目的更多支持；以及4.招聘更多的教员，以加强现有项目并支持额外的项目开发。

DESCRIPTION: (Applicant's Description) The newly-organized Baylor College of Medicine Cancer Center (BCMCC) seeks a P20 Planning Grant with the aim of submitting a P30 application for an NCI Cancer Center Support Grant and being designated a Comprehensive Cancer Center in the next 24-36 months. Our overall Goal is to unify and organize strong, independent scientific programs into a well-functioning Cancer Center. The BCMCC serves Baylor College of Medicine (BCM) and four large teaching hospitals (Ben Taub General Hospital, The Methodist Hospital, Texas Children's Hospital, and the Houston Veterans Administration Hospital) which in 2001 saw 5,000 new cancer cases. BCM has >$50 million in cancer research support with ~$34 million from NCI. Basic, translational, and clinical research are conducted in eight Programs: Breast Cancer (led by C. Kent Osborne, M.D.); Cancer Biology (led by Dennis R. Roop, Ph.D.); Cancer Prevention and Population Sciences (led by Powel H. Brown, M.D., Ph.D.); Cell and Gene Therapy (led by Malcolm K. Brenner, M.D., Ph.D.); Cell Cycle Control, Tumor Suppressors, Viruses, and Oncogenes (led by J. Wade Harper, Ph.D.); Nuclear Receptor Biology (led by Orla M. Conneely, Ph.D.); Prostate Cancer (led by Timothy C. Thompson, Ph.D.); and Pediatric Cancer (led by David G. Poplack, M.D.). Fourteen Shared Resources/Cores support this effort. Michael W. Lieberman, M.D., Ph.D., serves as Center Director and reports directly to the President of BCM. Associate Directors include: Bert W. O'Malley, M.D. (Basic Science); Dr. Osborne (Clinical Science); Dr. Brown (Cancer Prevention, Outreach, and Health Services); and Ms. Barbara G. Cochran (Administration). Governance rests in the hands of an Executive Committee chaired by Dr. Lieberman and composed of the four Associate Directors and seven other BCMCC members. Harold L. Moses, M.D., chairs the External Advisory Committee, and Susan M. Berget, Ph.D., chairs the Internal Advisory Committee. To prepare for a P30 application, we have developed a detailed Strategic Plan with timelines. Our P20 Specific Goals are: 1. To Strengthen Administrative Leadership, Internal Governance, and Institutional Support for the BCMCC; 2. To Increase Interactions among BCMCC Members and Promote Translational Research; 3. To Develop Increased Support for Programs in the Shared Resources/Cores; and 4. To Recruit Additional Faculty to Strengthen Existing Programs and Support Additional Program Development.